Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study (CRAB)

Clinical Trial ID NCT00842686

Rank	Title	Journal	Year	PubWeight™‹?›
1	Preoperative versus postoperative chemoradiotherapy for rectal cancer.	N Engl J Med	2004	25.68
2	Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.	J Clin Oncol	2005	3.83
3	Preoperative radiotherapy for resectable rectal cancer: A meta-analysis.	JAMA	2000	2.76
4	Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.	J Clin Oncol	2002	1.54
5	Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.	Int J Radiat Oncol Biol Phys	2007	1.28
6	Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.	J Clin Oncol	2007	1.23
7	Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.	Radiat Oncol	2011	0.92
8	Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.	Croat Med J	2006	0.88